Arab Finance: Ibnsina Pharma (ISPH) registered a 15.6% year-on-year (YoY) decline in consolidated profit attributable to the parent company during the first six months of 2022, recording EGP 88.609 million, according to financial statements filed to the Egyptian Exchange (EGX) on August 14^th.

The company’s net sales rose to EGP 10.261 billion in the six-month period ended June 30^th from EGP 10.123 billion a year earlier.

Ibnsina’s standalone net profit after tax decreased to EGP 86.907 million by the end of June from EGP 106.713 million the year before.

Established in 2001, Ibnsina Pharma is the second-largest pharmaceutical distributor in Egypt, distributing products from over 350 global and local companies to more than 46,000 customers of pharmacies, hospitals, wholesalers, and healthcare institutions.